***STARTS IN 1 HOUR 1PM ET***: Barclays Hosted: Expert Call on PKU Treatment Landscape: PTCT's Sephience & BMRN's Palynziq

Research evidence excerpt

***STARTS IN 1 HOUR 1PM ET***: Barclays Hosted: Expert Call on PKU Treatment Landscape: PTCT's Sephience & BMRN's Palynziq

Metabolic Screening Program at the Children's Hospital of Philadelphia. Dr. Ficicioglu is

board-certified in pediatrics, medical genetics, and biochemical genetics, and he

specializes in biochemical genetics and metabolic disease. His interests include the study

of outcomes in expanded newborn screening, enzyme replacement treatment on

lysosomal storage diseases, fatty acid oxidation defects, PKU, and bone marrow

transplantation for inborn errors in metabolism. Dr. Ficicioglu's research has been

published in the Journal of Inherited Metabolic Disease, the Turkish Journal of Medical &

Biological Research, the Turkish Journal of Pediatrics, Neuropediatrics, the Istanbul Cocuk

Klinigi Dergisi, and Pediatric Neurology. He is the author of a publication on Fabry disease,

has spoken at conferences on topics specific to Fabry disease, and has served as an

investigator on a clinical trial for Fabry disease. He is personally responsible for prescribing

enzyme replacement therapy and substrate reduction therapy to his Fabry disease

patients. Dr. Ficicioglu received his MD from the University of Istanbul Cerrahpasa Medical

School and earned his PhD at the University of Marmara in Turkey. He completed a clinical

fellowship in the Division of Genetics and Metabolism at Harvard Medical School and the

Children's Hospital of Boston.

Meet the Analyst

Eliana Merle, CFA, joined Barclays in November 2025 as an

Equity Research Analyst to cover U.S. Small & Mid Cap

Biotechnology. She has over a decade of sell-side equity

research experience in the sector; most recently, Ellie

worked as a Senior Equity Research Analyst at UBS in

Biotechnology for five years.